Clinical Trial Update: Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment [Phase 2]

View source ↗

Summary

Phase 2 study of Denufosol (INS37217) in subjects with rhegmatogenous retinal detachment has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinal Detachment

Drugs mentioned

• Denufosol

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Retinal Detachment | Phase 2 | Status: TERMINATED